Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27383260,Cmax,"Timolol concentrations in aqueous humor after Taf/T-FDC instillation were higher than those after Lat/T-FDC instillation (Cmax, 3870 ng/mL vs 1330 ng/mL; AUCinf, 3970 ng·h/mL vs 1250 ng·h/mL).",Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27383260/),[ng] / [ml],3870,531,DB00373,Timolol
,27383260,Cmax,"Timolol concentrations in aqueous humor after Taf/T-FDC instillation were higher than those after Lat/T-FDC instillation (Cmax, 3870 ng/mL vs 1330 ng/mL; AUCinf, 3970 ng·h/mL vs 1250 ng·h/mL).",Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27383260/),[ng] / [ml],1330,532,DB00373,Timolol
,27383260,AUCinf,"Timolol concentrations in aqueous humor after Taf/T-FDC instillation were higher than those after Lat/T-FDC instillation (Cmax, 3870 ng/mL vs 1330 ng/mL; AUCinf, 3970 ng·h/mL vs 1250 ng·h/mL).",Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27383260/),[h·ng] / [ml],3970,533,DB00373,Timolol
,27383260,AUCinf,"Timolol concentrations in aqueous humor after Taf/T-FDC instillation were higher than those after Lat/T-FDC instillation (Cmax, 3870 ng/mL vs 1330 ng/mL; AUCinf, 3970 ng·h/mL vs 1250 ng·h/mL).",Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27383260/),[h·ng] / [ml],1250,534,DB00373,Timolol
,24607446,steady state drug flux,Ex vivo permeation across excised rabbit cornea showed an improved steady state drug flux (0.00052 mg cm(-2)min(-1)) and permeability co-efficient (1.7 × 10(-4)cmmin(-1)) for the RD-SOM compared to pure drug and a marketed eye drop preparation.,In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607446/),[mg] / [(cm)^2],0.00052,1715,DB00373,Timolol
,24607446,permeability co-efficient,Ex vivo permeation across excised rabbit cornea showed an improved steady state drug flux (0.00052 mg cm(-2)min(-1)) and permeability co-efficient (1.7 × 10(-4)cmmin(-1)) for the RD-SOM compared to pure drug and a marketed eye drop preparation.,In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607446/),1/[cmmin],1.7 × 10(-4),1716,DB00373,Timolol
,24607446,Cmax,In the case of a typical eye drop formulation a lower Cmax was obtained (1.97 ug/mL).,In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607446/),[ug] / [ml],1.97,1717,DB00373,Timolol
,1452619,lower detection limit,The lower detection limit for the assay was found to be 1 ng/ml from 1 ml of plasma.,Assay of timolol in human plasma using gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1452619/),[ng] / [ml],1,10731,DB00373,Timolol
at least,1452619,recovery,A recovery of at least 80% of timolol was found using the extraction method described.,Assay of timolol in human plasma using gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1452619/),%,80,10732,DB00373,Timolol
,18800867,peak concentration,"TLA reached a mean peak concentration of 3.705 +/- 0.3012 microg/mL at 15 min, tapering to 0.539 +/- 0.1431 microg/mL by 180 min.",Evaluation of aqueous humor concentrations of Istalol and Betimol following a single ocular instillation in rabbit eyes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800867/),[μg] / [ml],3.705,18229,DB00373,Timolol
,18800867,peak concentration,"TLA reached a mean peak concentration of 3.705 +/- 0.3012 microg/mL at 15 min, tapering to 0.539 +/- 0.1431 microg/mL by 180 min.",Evaluation of aqueous humor concentrations of Istalol and Betimol following a single ocular instillation in rabbit eyes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800867/),[μg] / [ml],0.539,18230,DB00373,Timolol
,18800867,peak concentration,"THH reached a mean peak concentration of 2.239 +/- 0.1430 microg/mL at 15 min postinstillation, tapering to 0.148 +/- 0.0282 microg/mL by 180 min.",Evaluation of aqueous humor concentrations of Istalol and Betimol following a single ocular instillation in rabbit eyes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800867/),[μg] / [ml],2.239,18231,DB00373,Timolol
,18800867,peak concentration,"THH reached a mean peak concentration of 2.239 +/- 0.1430 microg/mL at 15 min postinstillation, tapering to 0.148 +/- 0.0282 microg/mL by 180 min.",Evaluation of aqueous humor concentrations of Istalol and Betimol following a single ocular instillation in rabbit eyes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18800867/),[μg] / [ml],0.148,18232,DB00373,Timolol
,16315032,maximum plasma concentrations (C(max),"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[ng] / [ml],2.63,18488,DB00373,Timolol
,16315032,maximum plasma concentrations (C(max),"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[ng] / [ml],2.94,18489,DB00373,Timolol
,16315032,elimination half-lives ( T(1/2),"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),h,5.49,18490,DB00373,Timolol
,16315032,elimination half-lives ( T(1/2),"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),h,6.75,18491,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[h·ng] / [ml],19.54,18492,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[h·ng] / [ml],23.25,18493,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[ng] / [ml],1.73,18494,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),h,3.30,18495,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[h·ng] / [ml],11.32,18496,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[ng] / [ml],1.60,18497,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),h,3.24,18498,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[h·ng] / [ml],8.52,18499,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[ng] / [ml],1.23,18500,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),[ng] / [ml],1.67,18501,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),h,2.22,18502,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),h,2.52,18503,DB00373,Timolol
,16315032,area-under-curve (AUC,"Among healthy volunteers using aqueous timolol, poor metabolisers (PMs, n=2) of CYP2D6 had higher maximum plasma concentrations (C(max), values 2.63 and 2.94 ng/ml), longer elimination half-lives ( T(1/2), 5.49 and 6.75 h), and higher area-under-curve (AUC, 19.54 and 23.25 ng.h/ml) than intermediate [IMs, n=6, mean+/-SD 1.73+/-0.59 ng/ml (not significant), 3.30+/-0.48 h, 11.32+/-3.72 ng.h/ml], extensive (EMs, n=8, 1.60+/-0.72 ng/ml, 3.24+/-1.24 h, 8.52+/-6.12 ng.h/ml) and ultra-rapid (UMs, n=2, values 1.23 and 1.67 ng/ml, 2.22 and 2.52 h, 6.16 and 6.94 ng.h/ml) metabolisers.","Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16315032/),,6.16,18504,DB00373,Timolol
,12107508,(C(max),"The peak concentration of ophthalmic timolol in plasma, (C(max)=1.14+/-0.34 ng/ml, mean+/-SD, n=8) was measured in most subjects within 15 min after drug administration.",Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107508/),[ng] / [ml],1.14,21078,DB00373,Timolol
,12107508,area under the curve from zero to infinitum (AUC(0-)(infinity)),"The mean area under the curve from zero to infinitum (AUC(0-)(infinity)) was 6.46+/-2.49 ng/ml per hour after intravenous and 4.78+/-1.90 ng/ml per hour (means+/-SD, n=8) after ocular administration.",Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107508/),[ng] / [h·ml],6.46,21079,DB00373,Timolol
,12107508,area under the curve from zero to infinitum (AUC(0-)(infinity)),"The mean area under the curve from zero to infinitum (AUC(0-)(infinity)) was 6.46+/-2.49 ng/ml per hour after intravenous and 4.78+/-1.90 ng/ml per hour (means+/-SD, n=8) after ocular administration.",Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107508/),[ng] / [h·ml],4.78,21080,DB00373,Timolol
,12107508,systemic bioavailability (F),"The systemic bioavailability (F) of the eyedrop was 78.0+/-24.5% (mean+/-SD, n=8).",Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12107508/),%,78.0,21081,DB00373,Timolol
,17582643,LCST,"PNIPAAm-CS had a LCST of 32 degrees C, which is close to the surface temperature of the eye.",Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17582643/),degrees,32,27159,DB00373,Timolol
,17582643,C(max),"The C(max) of timolol maleate in aqueous fluid for the PNIPAAm-CS solution was 11.2 microg/ml, which is two-fold higher than that of the conventional eye drop, along with greater AUC.",Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17582643/),[μg] / [ml],11.2,27160,DB00373,Timolol
,7758979,occupancy,"The beta 1- and beta 2-receptor occupancy decreased slowly and was on average 38% and 64%, respectively, 12 h after the single dose.",Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758979/),%,38,38936,DB00373,Timolol
,7758979,occupancy,"The beta 1- and beta 2-receptor occupancy decreased slowly and was on average 38% and 64%, respectively, 12 h after the single dose.",Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758979/),%,64,38937,DB00373,Timolol
,7758979,area under concentration-time curve,The calculated mean area under concentration-time curve of timolol in plasma was 10.28 ng/ml per hour and the mean half-life was 4.8 h.,Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758979/),[ng] / [h·ml],10.28,38938,DB00373,Timolol
,7758979,half-life,The calculated mean area under concentration-time curve of timolol in plasma was 10.28 ng/ml per hour and the mean half-life was 4.8 h.,Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758979/),h,4.8,38939,DB00373,Timolol
,8103764,half-life for the elimination phase,Timolol was eliminated from plasma with a mean half-life for the elimination phase of 2.6 hours.,The analysis of plasma kinetics and beta-receptor binding and -blocking activity of timolol following its small intravenous dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8103764/),h,2.6,51856,DB00373,Timolol
,7215417,peaks plasma concentration (Cmax),Individual variation was observed in bioavailability; the peaks plasma concentration (Cmax) of 50 to 103 ng/ml being achieved at different times(0.5--3h).,Pharmacokinetics of oral timolol studied by mass fragmentography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215417/),[ng] / [ml],50 to 103,57352,DB00373,Timolol
,7215417,residual level,The residual level after 12 h differed greatly between the subjects (0.8 to 7.2 ng/ml).,Pharmacokinetics of oral timolol studied by mass fragmentography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215417/),[ng] / [ml],0.8 to 7.2,57353,DB00373,Timolol
,7215417,half-life of the terminal elimination phase,The mean half-life of the terminal elimination phase was 2.62 +/- 0.17 h.,Pharmacokinetics of oral timolol studied by mass fragmentography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215417/),h,2.62,57354,DB00373,Timolol
,7215417,renal to body clearance ratio,"Extra-renal elimination (metabolic and biliary) represented the main route of elimination, with a renal to body clearance ratio of 0.123.",Pharmacokinetics of oral timolol studied by mass fragmentography. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215417/),,0.123,57355,DB00373,Timolol
,20437246,Peak concentration,"Peak concentration of drug in aqueous humor from TMREV(bio) (12.46 microg/ml achieved at 60 min) was almost 1.7 times that of the control drug solution (TMS, 0.25%; 7.2 microg/ml).",Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20437246/),[μg] / [ml],12.46,69148,DB00373,Timolol
,20437246,Peak concentration,"Peak concentration of drug in aqueous humor from TMREV(bio) (12.46 microg/ml achieved at 60 min) was almost 1.7 times that of the control drug solution (TMS, 0.25%; 7.2 microg/ml).",Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20437246/),%,0.25,69149,DB00373,Timolol
,20437246,Peak concentration,"Peak concentration of drug in aqueous humor from TMREV(bio) (12.46 microg/ml achieved at 60 min) was almost 1.7 times that of the control drug solution (TMS, 0.25%; 7.2 microg/ml).",Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20437246/),[μg] / [ml],7.2,69150,DB00373,Timolol
,26391697,C max,"On both sampling days, concentrations peaked at 10 min after the dose, and were cleared from the blood circulation by 30 min; average C max ranged from 17 to 24 pg/mL, and AUC0-last from 3 to 5 pg*h/mL.","Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391697/),[pg] / [ml],17 to 24,70906,DB00373,Timolol
,26391697,AUC0-last,"On both sampling days, concentrations peaked at 10 min after the dose, and were cleared from the blood circulation by 30 min; average C max ranged from 17 to 24 pg/mL, and AUC0-last from 3 to 5 pg*h/mL.","Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391697/),[h·pg] / [ml],3 to 5,70907,DB00373,Timolol
,26391697,C max,Concentrations peaked at 15 min post-dose and diminished in a similar manner after 2 h; average C max was 800 pg/mL and AUC0-last 3900 pg*h/mL.,"Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391697/),[pg] / [ml],800,70908,DB00373,Timolol
,26391697,AUC0-last,Concentrations peaked at 15 min post-dose and diminished in a similar manner after 2 h; average C max was 800 pg/mL and AUC0-last 3900 pg*h/mL.,"Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391697/),[h·pg] / [ml],3900,70909,DB00373,Timolol
,7816756,peak timolol concentrations,"Timolol inserts afforded similar decreases in intraocular pressure in open-angle glaucoma patients as did b.i.d. eyedrops, but produced lower peak timolol concentrations in plasma, 0.70 +/- 0.10 ng/ml and 0.24 +/- 0.05 ng/ml, respectively.",Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7816756/),[ng] / [ml],0.70,71956,DB00373,Timolol
,7816756,peak timolol concentrations,"Timolol inserts afforded similar decreases in intraocular pressure in open-angle glaucoma patients as did b.i.d. eyedrops, but produced lower peak timolol concentrations in plasma, 0.70 +/- 0.10 ng/ml and 0.24 +/- 0.05 ng/ml, respectively.",Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7816756/),[ng] / [ml],0.24,71957,DB00373,Timolol
,7816756,tmax,"After eyedrops, peak concentrations were achieved at 15.0 +/- 2.2 min, while application of an insert resulted in a delayed peak (tmax = 623 +/- 195 min).",Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7816756/),min,623,71958,DB00373,Timolol
,19912165,half-life,The in vivo half-life predicted for timolol was 3.7 hr.,Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),h,3.7,82486,DB00373,Timolol
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,1.4,82487,DB00373,Timolol
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,2.0,82488,DB00373,Timolol
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,3.5,82489,DB00373,Timolol
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,21,82490,DB00373,Timolol
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,20,82491,DB00373,Timolol
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.7,82492,DB00373,Timolol
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.5,82493,DB00373,Timolol
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,5.9,82494,DB00373,Timolol
,27660724,oral bioavailability (F%),"The drug suffers from extensive first pass effect, resulting in a reduction of oral bioavailability (F%) to 50% and a short elimination half-life of 4 h; parameters necessitating its frequent administration.","Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),%,50,85871,DB00373,Timolol
,27660724,elimination half-life,"The drug suffers from extensive first pass effect, resulting in a reduction of oral bioavailability (F%) to 50% and a short elimination half-life of 4 h; parameters necessitating its frequent administration.","Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),h,4,85872,DB00373,Timolol
,27660724,%EE,"The optimized transfersomal gel was prepared with 4.65:1 PC:SAA molar ratio, 3:1 solvent volumetric ratio, and 13 mg drug amount with particle size of 2.722 μm, %EE of 39.96%, and a release rate of 134.49 μg/cm(2)/h.","Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),%,39.96,85873,DB00373,Timolol
,27660724,release rate,"The optimized transfersomal gel was prepared with 4.65:1 PC:SAA molar ratio, 3:1 solvent volumetric ratio, and 13 mg drug amount with particle size of 2.722 μm, %EE of 39.96%, and a release rate of 134.49 μg/cm(2)/h.","Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),[μg] / [cm(2)·h],134.49,85874,DB00373,Timolol
,27660724,permeation rate,The permeation rate of the optimized formulation through the rat skin was excellent (151.53 μg/cm(2)/h) and showed four times increase in relative bioavailability with prolonged plasma profile up to 72 h compared with oral aqueous solution.,"Improved bioavailability of timolol maleate via transdermal transfersomal gel: Statistical optimization, characterization, and pharmacokinetic assessment. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27660724/),[μg] / [cm(2)·h],151.53,85875,DB00373,Timolol
,28399267,concentration,The concentration of THC in the iris-ciliary bodies at the 60- and 120-minute time points (53 and 57.4 ng/50 mg) were significantly greater than that of THC-Val-HS (24.2 and 11.3 ng/50 mg).,Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399267/),,24.2,91446,DB00373,Timolol
,28399267,concentration,The concentration of THC in the iris-ciliary bodies at the 60- and 120-minute time points (53 and 57.4 ng/50 mg) were significantly greater than that of THC-Val-HS (24.2 and 11.3 ng/50 mg).,Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399267/),,11,91447,DB00373,Timolol
,3577707,Kel,"After ocular application of tracer labelled timolol, the radioactivity decreased slowly in the iris (Kel = 0.05 h-1) and ciliary body (Kel = 0.02 h-1).",The pharmacokinetics of ocularly applied timolol in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3577707/),1/[h],0.05,107966,DB00373,Timolol
,3577707,Kel,"After ocular application of tracer labelled timolol, the radioactivity decreased slowly in the iris (Kel = 0.05 h-1) and ciliary body (Kel = 0.02 h-1).",The pharmacokinetics of ocularly applied timolol in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3577707/),1/[h],0.02,107967,DB00373,Timolol
,3577707,Kel,In the aqueous humour the elimination rate was faster (Kel = 0.57 h-1).,The pharmacokinetics of ocularly applied timolol in rabbits. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3577707/),1/[h],0.57,107968,DB00373,Timolol
,8285070,Tmax,The pharmacokinetic parameters are: Tmax = 18.8 h; Cmax = 11.2 ng/ml; AUC = 265.7 ng/ml.h; Vss = 120.0 L; K = 0.084 h-1.,[The bioavailability of transdermal therapeutic system of timolol]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285070/),h,18.8,115298,DB00373,Timolol
,8285070,Cmax,The pharmacokinetic parameters are: Tmax = 18.8 h; Cmax = 11.2 ng/ml; AUC = 265.7 ng/ml.h; Vss = 120.0 L; K = 0.084 h-1.,[The bioavailability of transdermal therapeutic system of timolol]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285070/),[ng] / [ml],11.2,115299,DB00373,Timolol
,8285070,AUC,The pharmacokinetic parameters are: Tmax = 18.8 h; Cmax = 11.2 ng/ml; AUC = 265.7 ng/ml.h; Vss = 120.0 L; K = 0.084 h-1.,[The bioavailability of transdermal therapeutic system of timolol]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285070/),[ng] / [h·ml],265.7,115300,DB00373,Timolol
,8285070,Vss,The pharmacokinetic parameters are: Tmax = 18.8 h; Cmax = 11.2 ng/ml; AUC = 265.7 ng/ml.h; Vss = 120.0 L; K = 0.084 h-1.,[The bioavailability of transdermal therapeutic system of timolol]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285070/),l,120.0,115301,DB00373,Timolol
,8285070,K,The pharmacokinetic parameters are: Tmax = 18.8 h; Cmax = 11.2 ng/ml; AUC = 265.7 ng/ml.h; Vss = 120.0 L; K = 0.084 h-1.,[The bioavailability of transdermal therapeutic system of timolol]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8285070/),1/[h],0.084,115302,DB00373,Timolol
,738350,plasma half-life,"Mean plasma half-life after oral dosing was 4.86 h, and after intravenous administration it was 4.56 h; the difference was not significant.",Plasma timolol levels after oral and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/738350/),h,4.86,118502,DB00373,Timolol
,738350,plasma half-life,"Mean plasma half-life after oral dosing was 4.86 h, and after intravenous administration it was 4.56 h; the difference was not significant.",Plasma timolol levels after oral and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/738350/),h,4.56,118503,DB00373,Timolol
,738350,volume of distribution,The volume of distribution was 3.5 1/k.,Plasma timolol levels after oral and intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/738350/),[1] / [k],3.5,118504,DB00373,Timolol
,8359190,bioavailability,"When the 20% (w/v) timolol patch was applied, the mean bioavailability was 74.4%.",Pharmacokinetics and beta-blocking effects of transdermal timolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359190/),%,74.4,123187,DB00373,Timolol
,8359190,bioavailability,"Plasma timolol concentrations were below the detection limit when a 5% patch was applied to the same skin area in all four subjects, except for one in whom the bioavailability was 23.6%.",Pharmacokinetics and beta-blocking effects of transdermal timolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359190/),%,23.6,123188,DB00373,Timolol
,32043,potency ratios,"The mean potency ratios of timolol to propranolol as an antagonist of chronotropic effects on exercise tachycardia were 11 to 17 and 3.6 to 5.5 in dose- and concentration-effect relationships, respectively.",Comparison of disposition and effect of timolol and propranolol on exercise tachycardia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043/),,11 to 17,132123,DB00373,Timolol
,32043,potency ratios,"The mean potency ratios of timolol to propranolol as an antagonist of chronotropic effects on exercise tachycardia were 11 to 17 and 3.6 to 5.5 in dose- and concentration-effect relationships, respectively.",Comparison of disposition and effect of timolol and propranolol on exercise tachycardia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043/),,3.6 to 5.5,132124,DB00373,Timolol
,19126429,relative bioavailability (F(rel)),The extent of absorption of TM-SE patch expressed by AUC was 64% larger as compared to the oral solution with steady plasma concentration over 18 h and relative bioavailability (F(rel)) of 163%.,Novel transdermal delivery of Timolol maleate using sugar esters: preclinical and clinical studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19126429/),%,163,136487,DB00373,Timolol
,7248483,fraction of,"The means of the fraction of the administered oral dose reaching the systemic circulations intact drug were calculated to be 0.58 and 0.60 for normal volunteers and uremic patients, respectively.",Estimation of the systemic bioavailability of timolol in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248483/),,0,153986,DB00373,Timolol
,7248483,fraction of,"The means of the fraction of the administered oral dose reaching the systemic circulations intact drug were calculated to be 0.58 and 0.60 for normal volunteers and uremic patients, respectively.",Estimation of the systemic bioavailability of timolol in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248483/),,0.60,153987,DB00373,Timolol
,721948,overall elimination half-life,"After the single oral doses, overall elimination half-life was 3.2 +/- 0.2 hours (mean +/- S.E.M.), with an observed peak time of 2.0 +/- 0.2 hours; extrapolated volume of distribution was 1.81 +/- 0.15 liter/kg; and the total plasma clearance was 557 +/- 61 ml/min.",Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/721948/),h,3.2,160912,DB00373,Timolol
,721948,observed peak time,"After the single oral doses, overall elimination half-life was 3.2 +/- 0.2 hours (mean +/- S.E.M.), with an observed peak time of 2.0 +/- 0.2 hours; extrapolated volume of distribution was 1.81 +/- 0.15 liter/kg; and the total plasma clearance was 557 +/- 61 ml/min.",Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721948/),h,2.0,160913,DB00373,Timolol
,721948,volume of distribution,"After the single oral doses, overall elimination half-life was 3.2 +/- 0.2 hours (mean +/- S.E.M.), with an observed peak time of 2.0 +/- 0.2 hours; extrapolated volume of distribution was 1.81 +/- 0.15 liter/kg; and the total plasma clearance was 557 +/- 61 ml/min.",Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721948/),[l] / [kg],1.81,160914,DB00373,Timolol
,721948,total plasma clearance,"After the single oral doses, overall elimination half-life was 3.2 +/- 0.2 hours (mean +/- S.E.M.), with an observed peak time of 2.0 +/- 0.2 hours; extrapolated volume of distribution was 1.81 +/- 0.15 liter/kg; and the total plasma clearance was 557 +/- 61 ml/min.",Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721948/),[ml] / [min],557,160915,DB00373,Timolol
,7140133,bioavailability (F,Timolol had greater bioavailability (F = 0.61 +/- 0.06(SEM) and 0.32 +/- 0.04) and lower systemic clearance (463 +/- 74 ml kg-1 hr-1 and 1040 +/- 120 ml kg-1 hr-1) than propranolol.,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),,0.61,162767,DB00373,Timolol
,7140133,bioavailability (F,Timolol had greater bioavailability (F = 0.61 +/- 0.06(SEM) and 0.32 +/- 0.04) and lower systemic clearance (463 +/- 74 ml kg-1 hr-1 and 1040 +/- 120 ml kg-1 hr-1) than propranolol.,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),,0.32,162768,DB00373,Timolol
,7140133,systemic clearance,Timolol had greater bioavailability (F = 0.61 +/- 0.06(SEM) and 0.32 +/- 0.04) and lower systemic clearance (463 +/- 74 ml kg-1 hr-1 and 1040 +/- 120 ml kg-1 hr-1) than propranolol.,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),[ml] / [h·kg],463,162769,DB00373,Timolol
,7140133,systemic clearance,Timolol had greater bioavailability (F = 0.61 +/- 0.06(SEM) and 0.32 +/- 0.04) and lower systemic clearance (463 +/- 74 ml kg-1 hr-1 and 1040 +/- 120 ml kg-1 hr-1) than propranolol.,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),[ml] / [h·kg],1040,162770,DB00373,Timolol
,7140133,Half-lifes,Half-lifes were of the same order (2.7 and 2.9 hr).,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),h,2.7,162771,DB00373,Timolol
,7140133,Half-lifes,Half-lifes were of the same order (2.7 and 2.9 hr).,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),h,2.9,162772,DB00373,Timolol
,15811205,systemic bioavailability,"TLA was relatively comfortable, with a safety profile consistent with further clinical development, and, with bid dosing (exaggerated [2X] that anticipated for clinical use), had a systemic bioavailability similar to that of TIM 0.5%, bid.","Timolol LA: a double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15811205/),%,0.5,163619,DB00373,Timolol
,17431033,K(m),The K(m) value for the formation of M1 was 23.8 microM in human liver microsomes.,Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),μM,23.8,166307,DB00373,Timolol
,17431033,K(i),"The CYP2D6 inhibitor quinidine proved a potent competitive inhibitor of timolol metabolism, with an in vitro K(i) value of 0.08 microM.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),μM,0.08,166308,DB00373,Timolol
,17431033,half-life,"Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),h,3,166309,DB00373,Timolol
,17431033,half-life,"Judging from the disappearance of timolol in human liver homogenate, the in vivo half-life was extrapolated to be about 3 h, an estimate close to the half-life of about 2 to 5 h observed in vivo.",Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431033/),h,2 to 5,166310,DB00373,Timolol
,6840172,peak level (Cmax,"After fasting, the peak level (Cmax = 29.1 +/- 3.2 ng/ml; mean +/- SEM) was reached at 1.3 +/- 0.1 h (Tmax).","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],29.1,178034,DB00373,Timolol
,6840172,Tmax,"After fasting, the peak level (Cmax = 29.1 +/- 3.2 ng/ml; mean +/- SEM) was reached at 1.3 +/- 0.1 h (Tmax).","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),h,1.3,178035,DB00373,Timolol
,6840172,total area under the serum concentration-time curve (AUC0-infinity),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[h·ng] / [ml],154.4,178036,DB00373,Timolol
,6840172,total clearance (Cltot),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],751.5,178037,DB00373,Timolol
,6840172,renal clearance (Clren),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],97.2,178038,DB00373,Timolol
,6840172,elimination half-life (t1/2),"The total area under the serum concentration-time curve (AUC0-infinity) was 154.4 +/- 33.8 ng x h/ml, total clearance (Cltot) 751.5 +/- 90.6 ml/min, renal clearance (Clren) 97.2 +/- 10.1 ml/min, elimination half-life (t1/2) 2.9 +/- 0.3 h and 24-h recovery in urine (X0u-24) 11.1 +/- 1.4% of the dose.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),h,2.9,178039,DB00373,Timolol
,6840172,Cmax,"Dihydralazine enhanced Cmax (38.2 +/- 4.6 ng/ml) only when compared to phenobarbitone treatment, and did not affect any other parameters.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],38.2,178040,DB00373,Timolol
,6840172,Cmax,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ng] / [ml],25.5,178041,DB00373,Timolol
,6840172,AUC0-infinity,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),,117.5,178042,DB00373,Timolol
,6840172,Cltot,"Phenobarbitone pretreatment somewhat lowered Cmax (25.5 +/- 3.9 ng/ml), AUC0-infinity (117.5 +/- 22.1; p less than 0.05 vs food) and X0u-24 (8.7 +/- 1.2%), evidently by increasing Cltot (957.5 +/- 116.9 ml/min; p less than 0.05 vs food), but it did not affect Clren.","Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840172/),[ml] / [min],957.5,178043,DB00373,Timolol
,2864157,AUC,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),[h·ng] / [ml],1590,178394,DB00373,Timolol
,2864157,AUC,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),[h·ng] / [ml],394,178395,DB00373,Timolol
,2864157,t1/2,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),h,7.5,178396,DB00373,Timolol
,2864157,t1/2,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),h,3.7,178397,DB00373,Timolol
,2864157,oral clearance,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),[l] / [h],13.1,178398,DB00373,Timolol
,2864157,oral clearance,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),[l] / [h],48.5,178399,DB00373,Timolol
,31794668,clearance,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),[μl] / [min],6.44,180193,DB00373,Timolol
,31794668,volume of distribution,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),μl,687,180194,DB00373,Timolol
,31794668,volume of distribution,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),[μl] / [min],32.20,180195,DB00373,Timolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),min,73.87,180196,DB00373,Timolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),min,33.64,180197,DB00373,Timolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),[μl] / [min],32.20,180198,DB00373,Timolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),μl,1421,180199,DB00373,Timolol
,31794668,half-life,"Pharmacokinetic parameters were obtained using a compartmental fitting approach, and the estimated clearance, volume of distribution, and half-life values were the following: atenolol (6.44 μL/min, 687 μL, and 73.87 min), timolol (19.30 μL/min, 937 μL, and 33.64 min), and betaxolol (32.20 μL/min, 1421 μL, and 30.58 min).","Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794668/),min,30.58,180200,DB00373,Timolol
,639436,peak concentration (C max),"The mean peak concentration (C max) was 84.3 +/- 44.8 ng/ml at 0.8 +/- 0.4 hr for N and 87.1 +/- 22.8 ng/ml at 1.7 +/- 1.2 hr (p, NS) for MCRI.",Timolol kinetics in chronic renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639436/),[ng] / [ml],84.3,187510,DB00373,Timolol
,639436,peak concentration (C max),"The mean peak concentration (C max) was 84.3 +/- 44.8 ng/ml at 0.8 +/- 0.4 hr for N and 87.1 +/- 22.8 ng/ml at 1.7 +/- 1.2 hr (p, NS) for MCRI.",Timolol kinetics in chronic renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639436/),[ng] / [ml],87.1,187511,DB00373,Timolol
,639436,half-lives,N and MCRI mean half-lives (5.2 +/- 2.6 hr and 4.0 +/- 1.2 hr) were not statistically different.,Timolol kinetics in chronic renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639436/),h,5.2,187512,DB00373,Timolol
,639436,half-lives,N and MCRI mean half-lives (5.2 +/- 2.6 hr and 4.0 +/- 1.2 hr) were not statistically different.,Timolol kinetics in chronic renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639436/),h,4.0,187513,DB00373,Timolol
,14567646,Cmax,Cmax (185.1 +/- 56.8 ng/ml) was reached at hour 3.,Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14567646/),[ng] / [ml],185.1,192387,DB00373,Timolol
,2388875,heart rate,"In part A, mean exercise (bicycle ergometry) heart rate (beats/min, bpm) was suppressed from baseline at 48 hours after the patch (p less than 0.05) in each case (1 patch 167 vs 131 bpm; 2 patches 165 vs 120 bpm; 3 patches 159 vs 120 bpm).",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),bpm,167,202950,DB00373,Timolol
,2388875,heart rate,"In part A, mean exercise (bicycle ergometry) heart rate (beats/min, bpm) was suppressed from baseline at 48 hours after the patch (p less than 0.05) in each case (1 patch 167 vs 131 bpm; 2 patches 165 vs 120 bpm; 3 patches 159 vs 120 bpm).",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),bpm,131,202951,DB00373,Timolol
,2388875,heart rate,"In part A, mean exercise (bicycle ergometry) heart rate (beats/min, bpm) was suppressed from baseline at 48 hours after the patch (p less than 0.05) in each case (1 patch 167 vs 131 bpm; 2 patches 165 vs 120 bpm; 3 patches 159 vs 120 bpm).",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),bpm,165,202952,DB00373,Timolol
,2388875,heart rate,"In part A, mean exercise (bicycle ergometry) heart rate (beats/min, bpm) was suppressed from baseline at 48 hours after the patch (p less than 0.05) in each case (1 patch 167 vs 131 bpm; 2 patches 165 vs 120 bpm; 3 patches 159 vs 120 bpm).",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),bpm,120,202953,DB00373,Timolol
,2388875,heart rate,"In part A, mean exercise (bicycle ergometry) heart rate (beats/min, bpm) was suppressed from baseline at 48 hours after the patch (p less than 0.05) in each case (1 patch 167 vs 131 bpm; 2 patches 165 vs 120 bpm; 3 patches 159 vs 120 bpm).",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),bpm,159,202954,DB00373,Timolol
,2388875,concentrations,"Mean plasma timolol concentrations at 48 hours after the patch for one, two, and three patches were 5, 11, and 14 ng/ml, respectively.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),ng,5,202955,DB00373,Timolol
,2388875,concentrations,"Mean plasma timolol concentrations at 48 hours after the patch for one, two, and three patches were 5, 11, and 14 ng/ml, respectively.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),ng,11,202956,DB00373,Timolol
,2388875,concentrations,"Mean plasma timolol concentrations at 48 hours after the patch for one, two, and three patches were 5, 11, and 14 ng/ml, respectively.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),ng,14,202957,DB00373,Timolol
,2388875,heart rate,"For part B, mean exercise heart rate at baseline, 24, and 168 hours was 161, 113, and 130 bpm (p less than 0.05), and mean plasma timolol concentrations at these times were 0, 23, and 4 ng/ml.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),bpm,161,202958,DB00373,Timolol
,2388875,heart rate,"For part B, mean exercise heart rate at baseline, 24, and 168 hours was 161, 113, and 130 bpm (p less than 0.05), and mean plasma timolol concentrations at these times were 0, 23, and 4 ng/ml.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),bpm,113,202959,DB00373,Timolol
,2388875,heart rate,"For part B, mean exercise heart rate at baseline, 24, and 168 hours was 161, 113, and 130 bpm (p less than 0.05), and mean plasma timolol concentrations at these times were 0, 23, and 4 ng/ml.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),bpm,130,202960,DB00373,Timolol
,2388875,concentrations,"For part B, mean exercise heart rate at baseline, 24, and 168 hours was 161, 113, and 130 bpm (p less than 0.05), and mean plasma timolol concentrations at these times were 0, 23, and 4 ng/ml.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),ng,0,202961,DB00373,Timolol
,2388875,concentrations,"For part B, mean exercise heart rate at baseline, 24, and 168 hours was 161, 113, and 130 bpm (p less than 0.05), and mean plasma timolol concentrations at these times were 0, 23, and 4 ng/ml.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),ng,23,202962,DB00373,Timolol
,2388875,concentrations,"For part B, mean exercise heart rate at baseline, 24, and 168 hours was 161, 113, and 130 bpm (p less than 0.05), and mean plasma timolol concentrations at these times were 0, 23, and 4 ng/ml.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),ng,4,202963,DB00373,Timolol
,2388875,50% inhibitory (IC50) concentration,"The relationship between suppression of exercise heart rate and plasma timolol concentrations within subjects was well described by an inhibitory EMAX model, where EMAX ranged from a suppression of 42-65 bpm associated with a 50% inhibitory (IC50) concentration that ranged from 2-4 ng/ml.",Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2388875/),[ng] / [ml],2-4,202964,DB00373,Timolol
,26325164,AUC0-4,"The aqueous humor concentration of the second administered drug (tafluprost) was not affected by the dosing conditions, whereas the concentration of the first instilled drug (timolol) without the interval was lower than that with a 5-min interval (1,200 ng · h/mL vs. 1,890 ng · h/mL in AUC0-4) in rats.",Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325164/),[h·ng] / [ml],"1,200",203074,DB00373,Timolol
,26325164,AUC0-4,"The aqueous humor concentration of the second administered drug (tafluprost) was not affected by the dosing conditions, whereas the concentration of the first instilled drug (timolol) without the interval was lower than that with a 5-min interval (1,200 ng · h/mL vs. 1,890 ng · h/mL in AUC0-4) in rats.",Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26325164/),[h·ng] / [ml],"1,890",203075,DB00373,Timolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,0.07,207370,DB00373,Timolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,1.22,207371,DB00373,Timolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,1.51,207372,DB00373,Timolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,3.82,207373,DB00373,Timolol
,32946960,o,"The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%).","Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946960/),%,4.31,207374,DB00373,Timolol
,14567635,mean residence time,The pharmacokinetic simulation model gave a realistic mean residence time for timolol in the cornea (57 min) and the aqueous humor (90 min).,Ocular pharmacokinetic modeling using corneal absorption and desorption rates from in vitro permeation experiments with cultured corneal epithelial cells. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14567635/),min,57,211035,DB00373,Timolol
,14567635,mean residence time,The pharmacokinetic simulation model gave a realistic mean residence time for timolol in the cornea (57 min) and the aqueous humor (90 min).,Ocular pharmacokinetic modeling using corneal absorption and desorption rates from in vitro permeation experiments with cultured corneal epithelial cells. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14567635/),min,90,211036,DB00373,Timolol
,7363532,detection limit,Plasma concentrations were never above 5 ng/ml and not always detectable (detection limit 1 to 2 ng/ml).,Absorption of ocular timolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363532/),[ng] / [ml],1 to 2,211875,DB00373,Timolol
,12086720,viscosity,The viscosity of formulations containing thickening agents was in the order of PF-MC 3%>PF-HPMC 2%>PF-CMC 2.5%>PF127 15%.,In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12086720/),%,3,217040,DB00373,Timolol
,12086720,viscosity,The viscosity of formulations containing thickening agents was in the order of PF-MC 3%>PF-HPMC 2%>PF-CMC 2.5%>PF127 15%.,In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12086720/),%,2,217041,DB00373,Timolol
,12086720,viscosity,The viscosity of formulations containing thickening agents was in the order of PF-MC 3%>PF-HPMC 2%>PF-CMC 2.5%>PF127 15%.,In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12086720/),%,2.5,217042,DB00373,Timolol
,12086720,viscosity,The viscosity of formulations containing thickening agents was in the order of PF-MC 3%>PF-HPMC 2%>PF-CMC 2.5%>PF127 15%.,In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12086720/),%,15,217043,DB00373,Timolol
,8951683,flow rate,A reversed phase C18 column was used to separate samples with a flow rate of 0.8 mL/min and a UV detector set at 284 nm.,Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951683/),[ml] / [min],0.8,220987,DB00373,Timolol
,8951683,ka +kd,"For ka +kd, the eyedrop without a thickening agent had the highest value (0.160 min-1), followed by the eyedrop with a thickening agent (0.030 min-1), and the gel had the lowest value (0.009 min-1).",Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951683/),1/[min],0.160,220988,DB00373,Timolol
,8951683,ka +kd,"For ka +kd, the eyedrop without a thickening agent had the highest value (0.160 min-1), followed by the eyedrop with a thickening agent (0.030 min-1), and the gel had the lowest value (0.009 min-1).",Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951683/),1/[min],0.030,220989,DB00373,Timolol
,8951683,ka +kd,"For ka +kd, the eyedrop without a thickening agent had the highest value (0.160 min-1), followed by the eyedrop with a thickening agent (0.030 min-1), and the gel had the lowest value (0.009 min-1).",Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951683/),1/[min],0.009,220990,DB00373,Timolol
,8951683,AUC0 approximately infinity,"The AUC0 approximately infinity for the aqueous humor profile with time coordinates were 4142, 2974, and 1604 micrograms min/mL, for the gel, the eyedrop with a thickening agent, and the eyedrop without a thickening agent, respectively.",Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951683/),[min·μg] / [ml],4142,220991,DB00373,Timolol
,8951683,AUC0 approximately infinity,"The AUC0 approximately infinity for the aqueous humor profile with time coordinates were 4142, 2974, and 1604 micrograms min/mL, for the gel, the eyedrop with a thickening agent, and the eyedrop without a thickening agent, respectively.",Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951683/),[min·μg] / [ml],2974,220992,DB00373,Timolol
,8951683,AUC0 approximately infinity,"The AUC0 approximately infinity for the aqueous humor profile with time coordinates were 4142, 2974, and 1604 micrograms min/mL, for the gel, the eyedrop with a thickening agent, and the eyedrop without a thickening agent, respectively.",Pharmacokinetics and intraocular pressure lowering effect of timolol preparations in rabbit eyes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951683/),[min·μg] / [ml],1604,220993,DB00373,Timolol
,9593641,relative recovery,"In vitro relative recovery of the membrane with timolol and carteolol was approximately 17.5% and 21. 6%, respectively.",Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593641/),%,17.5,222869,DB00373,Timolol
,9593641,relative recovery,"In vitro relative recovery of the membrane with timolol and carteolol was approximately 17.5% and 21. 6%, respectively.",Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593641/),%,21. 6,222870,DB00373,Timolol
,9593641,Cmax,"The Cmax of carteolol (4.25 microg ml-1) was lower than that of timolol (5.52 microg ml-1), suggesting that the corneal permeability of timolol is higher than that of carteolol.",Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593641/),[μg] / [ml],4.25,222871,DB00373,Timolol
,9593641,Cmax,"The Cmax of carteolol (4.25 microg ml-1) was lower than that of timolol (5.52 microg ml-1), suggesting that the corneal permeability of timolol is higher than that of carteolol.",Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593641/),[μg] / [ml],5.52,222872,DB00373,Timolol
,9593641,Cmax,"After instillation of WP-934, the Cmax of timolol (12.32 microg ml-1) was 2.2-fold higher than that after instillation of Timoptol.",Pharmacokinetics of topical beta-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9593641/),[μg] / [ml],12.32,222873,DB00373,Timolol
<,11678162,peak plasma concentrations,"For all subjects, peak plasma concentrations of timolol averaged <0.3 ng/ml within 4 hours after the last dose.",Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678162/),[ng] / [ml],0.3,229216,DB00373,Timolol
,11678162,peak plasma concentrations,"Timolol solution: For all subjects, peak plasma concentrations of timolol averaged about 0.5 ng/ml and 0.3 ng/ml within 4 hours following the first and second dose, respectively, on Day 8.",Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678162/),[ng] / [ml],0.5,229217,DB00373,Timolol
,11678162,peak plasma concentrations,"Timolol solution: For all subjects, peak plasma concentrations of timolol averaged about 0.5 ng/ml and 0.3 ng/ml within 4 hours following the first and second dose, respectively, on Day 8.",Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678162/),[ng] / [ml],0.3,229218,DB00373,Timolol
,27760378,EE%,The resulting TM-CHL was the most promising formulation with a mean particle size of 150.7nm and an EE% of 75.83±1.61%.,Bioadhesive chitosan-loaded liposomes: A more efficient and higher permeable ocular delivery platform for timolol maleate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27760378/),%,75.83,236175,DB00373,Timolol
,27760378,maximum intraocular pressure(IOP),"Furthermore, pharmacodynamics results showed that the maximum intraocular pressure(IOP) produced by TM-CHL was (19.67±1.14) mmHg compared with the (23.80±1.49) mmHg for TM eye drops, revealing that TM-CHL was more effective in reducing the IOP.",Bioadhesive chitosan-loaded liposomes: A more efficient and higher permeable ocular delivery platform for timolol maleate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27760378/),mmh,19.67,236176,DB00373,Timolol
,27760378,maximum intraocular pressure(IOP),"Furthermore, pharmacodynamics results showed that the maximum intraocular pressure(IOP) produced by TM-CHL was (19.67±1.14) mmHg compared with the (23.80±1.49) mmHg for TM eye drops, revealing that TM-CHL was more effective in reducing the IOP.",Bioadhesive chitosan-loaded liposomes: A more efficient and higher permeable ocular delivery platform for timolol maleate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27760378/),mm,23.80,236177,DB00373,Timolol
,1686051,Ki,"With a Ki value of 0.39 nM and 0.36 nM for the beta-1 and beta-2 receptors, respectively, levobunolol shows the highest binding affinity to both beta receptors.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),nM,0.39,237280,DB00373,Timolol
,1686051,Ki,"With a Ki value of 0.39 nM and 0.36 nM for the beta-1 and beta-2 receptors, respectively, levobunolol shows the highest binding affinity to both beta receptors.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),nM,0.36,237281,DB00373,Timolol
,1686051,Ki,"The Ki values of timolol (1.97 nM for the beta-1 receptor and 2.0 nM for the beta-2 receptor) and of carteolol (0.83 nM and 0.85 nM for the beta-1 and beta-2 receptors, respectively) are characteristic of a nonspecific beta-blocker.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),nM,1.97,237282,DB00373,Timolol
,1686051,Ki,"The Ki values of timolol (1.97 nM for the beta-1 receptor and 2.0 nM for the beta-2 receptor) and of carteolol (0.83 nM and 0.85 nM for the beta-1 and beta-2 receptors, respectively) are characteristic of a nonspecific beta-blocker.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),nM,2.0,237283,DB00373,Timolol
,1686051,Ki,"The Ki values of timolol (1.97 nM for the beta-1 receptor and 2.0 nM for the beta-2 receptor) and of carteolol (0.83 nM and 0.85 nM for the beta-1 and beta-2 receptors, respectively) are characteristic of a nonspecific beta-blocker.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),nM,0.83,237284,DB00373,Timolol
,1686051,Ki,"The Ki values of timolol (1.97 nM for the beta-1 receptor and 2.0 nM for the beta-2 receptor) and of carteolol (0.83 nM and 0.85 nM for the beta-1 and beta-2 receptors, respectively) are characteristic of a nonspecific beta-blocker.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),nM,0.85,237285,DB00373,Timolol
,1686051,Ki,"On the contrary, betaxolol is a beta-1 specific antagonist (Ki of 23.33 nM) and has a very low binding affinity to the beta-2 receptor (Ki of 200.00 nM).",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),nM,23.33,237286,DB00373,Timolol
,1686051,Ki,"On the contrary, betaxolol is a beta-1 specific antagonist (Ki of 23.33 nM) and has a very low binding affinity to the beta-2 receptor (Ki of 200.00 nM).",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),nM,200.00,237287,DB00373,Timolol
,1686051,peak 1 hour plasma level,"Betaxolol has a peak 1 hour plasma level of 22.28 ng/ml, which is equivalent to only 3.08 times its Ki for the beta-1 receptor and 0.36 times its Ki for the beta-2 receptor; it has less systemic beta-1 blocking activity than the other three drugs and very minimal systemic beta-2 blocking activity.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],22.28,237288,DB00373,Timolol
,1686051,Peak aqueous humor concentrations,Peak aqueous humor concentrations of all 4 beta-blockers are extremely elevated at 1 hour after administration (timolol 1613.58 ng/ml; betaxolol 866.06 ng/ml; levobunolol 750.89 ng/ml; and carteolol 859.18 ng/ml).,Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],1613.58,237289,DB00373,Timolol
,1686051,Peak aqueous humor concentrations,Peak aqueous humor concentrations of all 4 beta-blockers are extremely elevated at 1 hour after administration (timolol 1613.58 ng/ml; betaxolol 866.06 ng/ml; levobunolol 750.89 ng/ml; and carteolol 859.18 ng/ml).,Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],866.06,237290,DB00373,Timolol
,1686051,Peak aqueous humor concentrations,Peak aqueous humor concentrations of all 4 beta-blockers are extremely elevated at 1 hour after administration (timolol 1613.58 ng/ml; betaxolol 866.06 ng/ml; levobunolol 750.89 ng/ml; and carteolol 859.18 ng/ml).,Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],750.89,237291,DB00373,Timolol
,1686051,Peak aqueous humor concentrations,Peak aqueous humor concentrations of all 4 beta-blockers are extremely elevated at 1 hour after administration (timolol 1613.58 ng/ml; betaxolol 866.06 ng/ml; levobunolol 750.89 ng/ml; and carteolol 859.18 ng/ml).,Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],859.18,237292,DB00373,Timolol
,1686051,Trough aqueous humor levels,Trough aqueous humor levels of levobunolol (43.38 ng/ml) and carteolol (92.81 ng/ml) remain elevated at least 300 times their Ki value.,Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],43.38,237293,DB00373,Timolol
,1686051,Trough aqueous humor levels,Trough aqueous humor levels of levobunolol (43.38 ng/ml) and carteolol (92.81 ng/ml) remain elevated at least 300 times their Ki value.,Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],92.81,237294,DB00373,Timolol
,1686051,trough aqueous humor levels,"On the contrary, 12-hour trough aqueous humor levels of timolol (33.67 ng/ml) and betaxolol (94.86 ng/ml) have decreased to 2 to 40 times their Ki value, which may explain their requirement for twice daily administration clinically.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],33.67,237295,DB00373,Timolol
,1686051,trough aqueous humor levels,"On the contrary, 12-hour trough aqueous humor levels of timolol (33.67 ng/ml) and betaxolol (94.86 ng/ml) have decreased to 2 to 40 times their Ki value, which may explain their requirement for twice daily administration clinically.",Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686051/),[ng] / [ml],94.86,237296,DB00373,Timolol
,11999762,recoveries,The solid-phase extraction methods were optimised for each beta-blocker and provided recoveries of 72.8% for timolol and 94.52% for oxprenolol.,Quantitative determination of oxprenolol and timolol in urine by capillary zone electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999762/),%,72.8,255901,DB00373,Timolol
,11999762,recoveries,The solid-phase extraction methods were optimised for each beta-blocker and provided recoveries of 72.8% for timolol and 94.52% for oxprenolol.,Quantitative determination of oxprenolol and timolol in urine by capillary zone electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999762/),%,94.52,255902,DB00373,Timolol
,25159439,flow rate,"The chromatographic separation was achieved on Gemini C18 column using a mobile phase of ACN: 30 mmol L(-1) potassium dihydrogen phosphate buffer containing 0.1% triethylamine, pH 3.5 (20:80, v/v) at a flow rate of 1 mL min(-1) and UV detection at 254 and 295 nm for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ml] / [min],1,257449,DB00373,Timolol
,25159439,limits of quantitation,"The described method showed better separation with enhanced sensitivities than the previously reported methods with limits of quantitation of 8.75 and 10.32 ng mL(-1) in aqueous solution and 15.97 and 23.53 ng mL(-1) in AH for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ng] / [ml],8.75,257450,DB00373,Timolol
,25159439,limits of quantitation,"The described method showed better separation with enhanced sensitivities than the previously reported methods with limits of quantitation of 8.75 and 10.32 ng mL(-1) in aqueous solution and 15.97 and 23.53 ng mL(-1) in AH for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ng] / [ml],10.32,257451,DB00373,Timolol
,25159439,limits of quantitation,"The described method showed better separation with enhanced sensitivities than the previously reported methods with limits of quantitation of 8.75 and 10.32 ng mL(-1) in aqueous solution and 15.97 and 23.53 ng mL(-1) in AH for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ng] / [ml],15.97,257452,DB00373,Timolol
,25159439,limits of quantitation,"The described method showed better separation with enhanced sensitivities than the previously reported methods with limits of quantitation of 8.75 and 10.32 ng mL(-1) in aqueous solution and 15.97 and 23.53 ng mL(-1) in AH for DOR and TIM, respectively.",Simultaneous determination of dorzolomide and timolol in aqueous humor: a novel salting out liquid-liquid microextraction combined with HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25159439/),[ng] / [ml],23.53,257453,DB00373,Timolol
,11863286,retention times,The retention times ranged from 5.72 to 11.25 min.,Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11863286/),min,5.72 to 11.25,267930,DB00373,Timolol
>,11863286,recovery,The recovery was >90%.,Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11863286/),%,90,267931,DB00373,Timolol
,28264602,oral bioavailability,The drug suffers from poor oral bioavailability (50%) due to its first pass effect and a short elimination half-life of 4 h; resulting in its frequent administration.,Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264602/),%,50,272083,DB00373,Timolol
,28264602,elimination half-life,The drug suffers from poor oral bioavailability (50%) due to its first pass effect and a short elimination half-life of 4 h; resulting in its frequent administration.,Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264602/),h,4,272084,DB00373,Timolol
,28264602,permeation rate,Optimized protransfersomal system had excellent permeation rate through shaved rat skin (780.69 μg/cm2/h) and showed six times increase in relative bioavailability with prolonged plasma profile up to 72 h.,Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28264602/),[μg] / [cm2·h],780.69,272085,DB00373,Timolol
